The 36-month beta value for CELU is at 0.79. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CELU is 10.76M, and currently, shorts hold a 8.68% of that float. The average trading volume for CELU on November 27, 2024 was 997.24K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CELU) stock’s latest price update
Celularity Inc (NASDAQ: CELU) has seen a decline in its stock price by -28.42 in relation to its previous close of 2.85. However, the company has experienced a -30.61% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-20 that FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that its strategic partner, Genting Berhad, has broken ground on Fontaine Vitale, a state-of-the-art stem cell and regenerative medicine facility in the Sanur Special Economic Zone located in Bali, Indonesia. Fontaine Vitale will offer world-class cell therapies focused on wellness, aesthetics, and regenerative medicine to both local and international patients using placenta-derived stem cells manufactured by Celularity in its US facility, according to Genting Berhad’s press release. The new center is expected to commence commercial operations towards the end of 2026.
CELU’s Market Performance
Celularity Inc (CELU) has experienced a -30.61% fall in stock performance for the past week, with a 20.71% rise in the past month, and a -31.73% drop in the past quarter. The volatility ratio for the week is 12.88%, and the volatility levels for the past 30 days are at 33.95% for CELU. The simple moving average for the past 20 days is -21.01% for CELU’s stock, with a -38.45% simple moving average for the past 200 days.
Analysts’ Opinion of CELU
Many brokerage firms have already submitted their reports for CELU stocks, with Morgan Stanley repeating the rating for CELU by listing it as a “Underweight.” The predicted price for CELU in the upcoming period, according to Morgan Stanley is $1 based on the research report published on January 30, 2023 of the previous year 2023.
H.C. Wainwright gave a rating of “Buy” to CELU, setting the target price at $15 in the report published on June 22nd of the previous year.
CELU Trading at -19.95% from the 50-Day Moving Average
After a stumble in the market that brought CELU to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.40% of loss for the given period.
Volatility was left at 33.95%, however, over the last 30 days, the volatility rate increased by 12.88%, as shares surge +48.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.20% lower at present.
During the last 5 trading sessions, CELU fell by -20.07%, which changed the moving average for the period of 200-days by -39.90% in comparison to the 20-day moving average, which settled at $2.60. In addition, Celularity Inc saw -17.54% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CELU starting from Lim Kok Thay, who purchase 21,410,983 shares at the price of $0.25 back on Jan 12 ’24. After this action, Lim Kok Thay now owns 51,473,762 shares of Celularity Inc, valued at $5,331,335 using the latest closing price.
Stock Fundamentals for CELU
Current profitability levels for the company are sitting at:
- -2.42 for the present operating margin
- 0.6 for the gross margin
The net margin for Celularity Inc stands at -2.64. The total capital return value is set at -1.53. Equity return is now at value -154.23, with -59.09 for asset returns.
Based on Celularity Inc (CELU), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -3.91. The debt to equity ratio resting at 0.19. The interest coverage ratio of the stock is -23.88.
Currently, EBITDA for the company is -183.95 million with net debt to EBITDA at -0.26. When we switch over and look at the enterprise to sales, we see a ratio of 1.75. The receivables turnover for the company is 3.17for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.26.
Conclusion
In conclusion, Celularity Inc (CELU) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
